Literature DB >> 6548316

Poor prognosis non-Hodgkin's lymphoma in the elderly: clinical presentation and management.

G M Mead, F R Macbeth, C J Williams, R D Ryall, D H Wright, J M Whitehouse.   

Abstract

Thirty-eight patients age 65 years and older with a diagnosis of non-Hodgkin's lymphoma of poor prognostic type were seen over a five and a half year period. These patients represented 19 per cent of our total new patient non-Hodgkin's lymphoma population during this time. Advanced age, coexisting medical illness, widespread lymphoma and poor treatment compliance were common problems. Despite this we were able to render 26 per cent of patients disease-free for periods from 12 to over 48 months. Age should not be considered a bar to staging and effective therapy. Palliative management was unsuccessful, and we believe that treatment should be given with the intention of cure. Features suggesting that a patient was more likely to achieve a lasting complete remission included early stage (I-IIA), a lack of systemic ('B') symptoms, an absence of bone marrow or bulky gastrointestinal tract disease and no pre-existing serious medical condition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6548316

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  3 in total

Review 1.  Modern management of non-Hodgkin's lymphoma.

Authors:  G M Mead; J M Whitehouse
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

2.  A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.

Authors:  N S Stuart; G R Blackledge; J A Child; J Fletcher; T J Perren; C J O'Brien; E L Jones; I O Ellis; J A Kavanagh; K A Kelly
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen.

Authors:  P Sonneveld; J J Michiels
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.